Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
Date:2/23/2012

more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.PDL BIOPHARMA, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS DATA(Unaudited)(In thousands, except per share amounts)Three Months EndedYear EndedDecember 31,December 31,2011201020112010RevenuesRoyalties$ 72,808$  74,629$ 351,641$ 343,475License and other-1,50010,4001,500Total revenues72,80876,129362,041344,975Operating ExpensesGeneral and administrative expenses4,82212,05618,33841,396Legal Settlement-92,500-92,500Total operating expenses4,822104,55618,338133,896Operating income (loss)67,986(28,427)343,703211,079Non-operating expense, netGain (loss) on retirement or conversion of convertible notes-1,033(766)(17,648)Interest and other income, net130131593468Interest expense(8,161)(9,514)(36,102)(43,529)Total non-operating expense, net(8,031)(8,350)(36,275)(60,709)Income befor
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... ANGELES , May 26, 2015 Pharmaco-Kinesis ... Board (NOCAB) recently convened at Shutters on the Beach ... review the development status of the Company,s innovative Metronomic ... designed to locally deliver chemotherapy over time to a ... dose delivery capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... 26, 2015 Mr. Kevin Xu , President ... Barack Obama and President Bill Clinton ... loss of Dr. Rongxiang Xu , Kevin,s father. ... ahead of his time, Dr. Xu,s commitment to the advancement ... legacy that will not be forgotten. As a renowned life ...
(Date:5/26/2015)... May 26, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a ... Luke M. Beshar to its Board of Directors. ... pharmaceutical industry expertise as Fluorinov accelerates its clinical development ... team, it is a pleasure to welcome Luke to ... impact on the strategy, financial strength and success of ...
(Date:5/26/2015)... PRC Clinical, the Clinical Trial ... Regenerative Medicine (ARM). The ARM counts more than ... commercialization of transformational treatments and cures for patients ... CRO focused in Clinical Trial Management, has developed ... research working with sponsors in the United States ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, Beyond A Legend 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 2PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 3
... ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, ... Institute of Allergy and Infectious Diseases (NIAID) at ... USA. The research collaboration involves formulating NIAID antigens ... potential vaccines for HIV and malaria. , "NIAID ...
... VIEW, California, February 25 BN,ImmunoTherapeutics, Inc. announced ... the vaccine was licensed from the National Institutes ... once again confirms the,excellent safety and efficacy results ... Cancers Symposium (GU) on February 26-28, 2009 in,Orlando, ...
... 25 Cerimon Pharmaceuticals, Inc., announced today ... once-daily topical diclofenac sodium patch Phase III program. ... III clinical studies with Cerimon,s diclofenac patch. The ... diclofenac patch compared to placebo for the treatment of ...
Cached Biology Technology:ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 3Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2
(Date:5/25/2015)... May 25, 2015  Australia,s market for wearable technologies ... 2014 saw the advent of several trials and prototypes. ... 2015 is expected to ignite interest in wearables as ... Australia . This in turn will spur ... drive new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... DALLAS , May 21, 2015 ... report, "Thermal Imaging Market by Solutions (Hardware, Software, Services), ... Veterinary, Automotive & others), by End-Users (Military & ... published by MarketsandMarkets, Thermal Imaging Market is expected ... $9998.9 Million by 2020, at a Compound Annual ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... WASHINGTON -- Recipients of the 10th annual Communication Awards ... National Academy of Engineering, and Institute of Medicine. ... part of the Keck Futures Initiative, these prestigious awards ... recognize excellence in reporting and communicating science, engineering, and ...
... Ghrelin is a hormone released by the lining of the ... help combat obesity -- in fact, a vaccine that lowers ... as a treatment for obesity. However, many people eat ... increase stress, its effectiveness as a treatment for obesity may ...
... RIVERSIDE, Calif. -- Turfgrass and landscape professionals will have the ... and management on Thursday, Sept. 13, 2012, at the University ... a.m. and ending at 2:30 p.m., will be held at ... King Blvd., Riverside. Parking will be available in ...
Cached Biology News:Daniel Kahneman's 'Thinking, Fast and Slow' wins best book award from academies 2Low ghrelin -- reducing appetite at the cost of increased stress? 2Turfgrass and Landscape Research Field Day to be held in California, Sept. 13 2
... for microRNA expression profiling ,miRCURY ... Locked Nucleic Acid (LNA) technology to provide ... short microRNA (miRNA) targets. miRCURY LNA Arrays ... RNA (no need for microRNA enrichment) labeled ...
... slightly cloudy liquid. Yellow, oily, bacterial ... each containing 10 ml of Freund's ... proportions by weight: 85% Drakeol 5NF, ... and 0.1% Mycobacterium butyricum ...
With sodium bicarbonate. Sterile, Cell culture tested...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Biology Products: